CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 14 enrolled
Drug / intervention
Docetaxel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01882985
NCT01882985Phase 2Completed
CompareCT.gov

A Phase II Study to Evaluate the Effects of Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients

University of California, Irvine·interventional·Posted Jun 21, 2013·Updated Jan 5, 2021

In Brief

A Phase 2 clinical trial evaluating Docetaxel and Lycopene for Adenocarcinoma of the Prostate and 5 related conditions. Completed, enrolled 14 participants across 1 site.

Detailed Summary

This phase II trial evaluated the impact of giving docetaxel together with lycopene supplements in treating patients with hormone-resistant prostate cancer not previously treated with chemotherapy. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoprevention is the use of certain drugs, such as lycopene, to keep cancer from forming. Giving docetaxel together with lycopene may be an effective treatment for prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 21, 2013
Enrollment StartDec 1, 2010
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 13.0 years ago

Interventions

Docetaxeldrug

Given IV

Lycopenedietary

Given PO